Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
Genomics02:02

Genomics

37.5K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
37.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

The Multiple Sclerosis Severity Allele rs10191329<sup>A</sup> and Cognitive Function: A UK Biobank Study.

Annals of clinical and translational neurology·2026
Same author

Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.

Journal of neuroinflammation·2026
Same author

DNA methylation mediates the multiple sclerosis onset risk associated with HHV-6 DNA positivity.

Environmental epigenetics·2026
Same author

Local genetic correlations between systemic sclerosis and common cancer types.

PloS one·2026
Same author

Association of Dietary Approaches to Stop Hypertension Diet With the Risk of Osteoporosis and Fracture: A Systematic Review and Meta-Analysis.

Food science & nutrition·2026

Related Experiment Video

Updated: Sep 17, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.5K

Multiomics integration prioritizes potential drug targets for multiple sclerosis.

Yuan Jiang1, Qianwen Liu1, Pernilla Stridh1

  • 1Department of Clinical Neuroscience, The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Centre for Molecular Medicine, Karolinska Institutet, Stockholm 17177, Sweden.

Proceedings of the National Academy of Sciences of the United States of America
|June 27, 2025
PubMed
Summary

This study identified 18 potential causal proteins in plasma and brain for multiple sclerosis (MS) drug discovery. Findings support repurposing existing drugs and developing new therapies for this immune-mediated disease.

Keywords:
causalgenomicsmultiple sclerosisproteomicstranscriptomics

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.9K
Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 17, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.5K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.9K
Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.3K

Area of Science:

  • Genetics and Genomics
  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an immune-mediated neurological disorder lacking a definitive cure.
  • Enhancing treatment efficacy and safety through novel drug discovery and repurposing is critical for managing MS.
  • Understanding the genetic and proteomic underpinnings of MS is essential for identifying new therapeutic targets.

Purpose of the Study:

  • To identify potential causal proteins associated with multiple sclerosis (MS) susceptibility using integrated omics data.
  • To explore the utility of these identified proteins as targets for drug discovery and repurposing in MS.
  • To elucidate the molecular pathways and interactions involved in MS pathogenesis.

Main Methods:

  • Integrative analysis of genome-wide association study (GWAS) data, protein quantitative trait loci (pQTL) from plasma and brain, and transcriptome data (bulk and cell-type specific).
  • Proteome-wide association study (PWAS) and summary-data-based Mendelian randomization (SMR) to identify and assess causality of MS-associated proteins.
  • HEIDI and Bayesian colocalization analyses to differentiate pleiotropy from linkage, followed by pathway and protein-protein interaction (PPI) network analysis.

Main Results:

  • Identified 18 potential causal proteins for MS, with nine each in plasma and brain, through rigorous statistical analyses.
  • Annotated 78 pathways and identified 16 existing non-MS drugs targeting six of the prioritized proteins, suggesting repurposing opportunities.
  • Revealed intricate protein-protein interactions (PPIs) among potential drug targets and existing MS drugs, highlighting interconnected biological networks.

Conclusions:

  • Prioritized 18 proteins in plasma and brain as potential therapeutic targets for multiple sclerosis (MS).
  • Provided evidence for drug repurposing by linking identified targets to existing medications and exploring PPI networks.
  • This research offers a foundation for developing novel therapeutic strategies and improving existing treatments for MS by elucidating underlying molecular mechanisms.